Ralliant (NYSE:RAL) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Ralliant (NYSE:RAL) from a buy rating to a hold rating in a research note released on Sunday morning.

Several other equities analysts have also weighed in on the stock. Oppenheimer upped their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. BMO Capital Markets initiated coverage on Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price for the company. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th. TD Cowen boosted their target price on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Finally, Evercore assumed coverage on Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.00.

Ralliant Stock Performance

Shares of RAL stock opened at $69.55 on Friday. The firm has a 50 day moving average of $66.43 and a 200-day moving average of $53.81. The company has a market cap of $7.78 billion and a price-to-earnings ratio of -6.36. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The company had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio is presently -1.83%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RAL. Dodge & Cox grew its holdings in shares of Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after buying an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new stake in shares of Ralliant in the 2nd quarter worth about $257,200,000. Millennium Management LLC lifted its position in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares in the last quarter. State Street Corp bought a new position in Ralliant in the 2nd quarter valued at about $213,096,000. Finally, Invesco Ltd. boosted its stake in Ralliant by 4.9% during the 4th quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after purchasing an additional 187,898 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.